|Have Questions?||Leave a Message or Start an on-line Chat|
The CDK6 recombinant monoclonal antibody is synthesized using protein technology and DNA recombinant technology. Initially, mice were injected with a synthesized peptide derived from human CDK6 to stimulate the immune response. After a certain period, the spleen was extracted from the mice under aseptic conditions, and the total RNA was isolated from the spleen cells. Subsequently, the cDNA was synthesized through RNA reverse transcription and used as a template for the PCR amplification of the CDK6 antibody gene. The obtained CDK6 antibody gene was then cloned into a vector and transfected into host cells for cultivation. The CDK6 recombinant monoclonal antibody was purified from the supernatant of cell culture using affinity chromatography. It has been thoroughly validated and can be used for detecting human CDK6 protein in ELISA, WB, and IP experiments.
CDK6 is a protein that plays an important role in cell cycle regulation. It is a serine/threonine protein kinase that forms complexes with D-type cyclins and phosphorylates the retinoblastoma protein (RB). This phosphorylation event releases the transcription factor E2F, which activates genes involved in DNA replication and cell cycle progression from G1 to S phase. CDK6 is involved in regulating the transition from the G1 phase to the S phase of the cell cycle. It is also involved in cell differentiation, immune system function, and tumorigenesis. Dysregulation of CDK6 activity has been implicated in a number of cancers.
Applications : Western blot
Sample type: Human Cells
Review: A representative blot of CDK1, CDK2, CDK4, CDK6, CDKN2B, and CDKN2D in HepG2 cells. Protein levels of CDK4 and 6 were decreased by tBHP whereas CDKN2B and CDKN2D were increased by tBHP in a dose-dependent manner.